

## Dates to Remember

### **CVCA 2008 Annual Conference**

May 28-30th, 2008

Montreal, QC

[www.cvca.ca](http://www.cvca.ca)

### **AFMNet's Fourth Annual Scientific Conference**

May 31-June 1st, 2008

Vancouver, BC

[www.afmnet.ca](http://www.afmnet.ca)

### **AFMNet Biopartnering Day**

June 2, 2008

Vancouver, BC

<http://www.afmnet.ca/asc/4/biopartnering.html>

### **2008 TechConnect Summit**

June 3-5th, 2008

Boston, MA

[www.techconnect.org/Summit2008](http://www.techconnect.org/Summit2008)

### **Mazankowski Alberta Heart Institute Inaugural Congress**

June 5-6th, 2008

Edmonton, AB

[www.mazankowskicongress.com](http://www.mazankowskicongress.com)

Cont. on Page 2

## Recent News

### **AVAC Investee Wins TEC VenturePrize**

Edmonton, Alberta. With over \$150,000 in cash and business development services on the line, Datagardens Inc., the winner of the Fast Growth Award walked away with an awards package valued at \$90,000. The TEC VenturePrize is a province wide business plan development competition that assists Alberta's entrepreneurs in creating a comprehensive plan to excel their vision into a viable venture. Through video-conference seminars delivered by the University of Alberta's School of Business, entrepreneurs learn the elements of a successful plan. Through partnerships and sponsorship winners and runners up gain access to vital resources to grow their businesses.

DataGardens has created technology that essentially creates a virtual data centre. Their solution is described as an evolution in how companies manage their IT infrastructure. Usually, companies have two ways of operating: they can either centralize everything in a main office, or they can spread their IT throughout branch offices. DataGardens expects to provide a virtualized solution that provides their customers the best of both worlds.

The award was achieved a month after AVAC committed to investment \$1 Million in DataGardens. [www.datagardens.com](http://www.datagardens.com)

### **New Partnership Forms Nationally Recognized Institute**

Edmonton, Canada - Capital Health, Caritas Health Group and the University of Alberta announce a new partnership that will cement Alberta's

Continued on Page 2

**nextMEDIA: Future of Digital Content**

*June 6-8th, 2008*

Banff, AB

[www.nextmediaevents.com](http://www.nextmediaevents.com)

**Westlink Annual Conference**

*June 16-18th, 2008*

Eau Claire Sheraton, Calgary, AB

[www.westlink.ca/annualconference/2008/](http://www.westlink.ca/annualconference/2008/)

**Bio International Convention**

*June 17-20th, 2008*

San Diego, CA

[www.bio2008.org](http://www.bio2008.org)

**IFT Annual Meeting & Food Expo**

*June 28-July 1st, 2008*

New Orleans, LA

[www.am-fe.ift.org/cms/](http://www.am-fe.ift.org/cms/)

**Banff Conference on Plant Metabolism**

*July 30-August 3rd, 2008*

Banff, AB

[www.ucalgary.ca/plantmetabolism](http://www.ucalgary.ca/plantmetabolism)

**ABIC 2008**

*August 24-27th, 2008*

Cork, Ireland

[www.abic.ca/abic2008/index.html](http://www.abic.ca/abic2008/index.html)

**Astech Awards Gala**

*October 24, 2008*

Edmonton, AB

[www.astech.ab.ca](http://www.astech.ab.ca)

position as an international leader in head and neck reconstruction and rehabilitation. The partnership formalizes the transformation of the Craniofacial Osseointegration and Maxillofacial Rehabilitation Unit (COMPRU) into the Institute for Reconstructive Sciences in Medicine (iRSM).

The strategic partnership will sustain iRSM's international excellence by improving access to needed services and ensuring a strong focus on quality, innovation, expertise, and new technologies. iRSM will continue to promote research, education and innovation.

iRSM provides complex and specialized services to patients with head and neck defects resulting from cancer, trauma, or congenital disease. It has earned an international reputation for innovation by combining expertise in diverse disciplines such as surgery, medicine, dentistry, rehabilitation medicine, engineering, and computing science to create a fully integrated environment for clinical care, research, education and training in reconstructive medicine and technology.

"This institute will build on the strong foundation formed by COMPRU. Researchers and health providers will work together to solve real world problems and to offer patients the benefit of access to leading edge technologies. iRSM integrates activity distributed throughout the Capital Health region, with the intent to create the pre-eminent international institute for reconstructive medicine and science," says Patrick Dumelie, President of Caritas Health Group.

## Ceapro Expands Its Markets for Organic Natural Active Ingredients into South Korea

Edmonton, Alberta – 22 April 2008 – Ceapro Inc. (CZO – TSX Venture) announced today the completion of a new marketing partnership and distribution agreement with Korean firm, East Hill Corporation. The agreement encompasses Ceapro's current range of seven, certified organic, natural active ingredients.

Founded in 1996, East Hill develops and distributes ingredients for the health and beauty industries, from facilities in Cheongbuk Province, South Korea. East Hill's many customers include the top three Korean cosmetic

Companies: Amore Pacific, LG (H&H) and the Face Shop.

Said Mr IK Joe, President of East Hill, "We are very pleased to enter into this agreement with Ceapro, and look forward to introducing their natural and organic products to our large market for cosmetics: the South Korean per

capita consumption of beauty products ranks in the top five in the world. We expect the combination of Ceapro's quality products and East Hill's strengths in marketing and formulation in the Asian market will provide the foundation for a very successful long-term partnership."

Ceapro President and CEO, Dr. Mark Redmond reaffirmed the Company's growth strategy of international market expansion. "We have announced recently distribution partnerships in France and the United States. Working with East Hill continues our strategy of partnering with notable regional and market sector specialists. By positioning our new compounds in the \$8 billion global market for natural organic cosmetics we fully expect to win over new customers to our products and expertise."

## **Botaneco Announces Launch of Second Generation Oleosome Product**

CALGARY, April 14/CNW/ - Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. (TSX: SBS), focused on the development and commercialization of oleosome technology in personal care, OTC and topical pharmaceutical markets, today announced the launch of its second generation oleosome product, Hydresia(TM) G2, at the In-Cosmetics 2008 exposition in Amsterdam.

Hydresia(TM) G2, a natural emulsion base, retains all of the functional

[News Cont.](#)

performance properties of Botaneco's first generation Hydresia(TM) product, while offering formulators the ability to develop products over a broader pH range (3.5-8.5). This will allow for the development of low pH exfoliants and anti-aging products that can provide consumers with the moisturization, skin health and aesthetic benefits that Hydresia(TM) brings to other finished formulations. In addition, Hydresia(TM) G2 uses a new globally accepted preservative system that will expand the use of oleosomes in European and other markets.

"Botaneco is committed to developing ingredients that allow our customers to provide differentiated products that offer both performance and aesthetic benefits to consumers," said Andrew Baum, President and CEO of Botaneco's parent company, SemBioSys. "Hydresia(TM) G2 can be used in moisturizers, hair and skin cleansers, lip care, color cosmetics, skin lighteners, sun care and baby care products just like our first generation Hydresia(TM) product. In addition to these applications, Hydresia(TM) G2 can also be used in products where requirement for low pH have precluded the use of Hydresia(TM).

Botaneco's proprietary Hydresia and Hydresia(TM) G2 products are natural emulsifiers comprised of oleosomes, natural oil carrying structures derived from safflower seeds.

## **Maker of Cold-fX(R) Opens New Headquarters and Research Facility in Edmonton Research Park**

EDMONTON, ALBERTA--(Marketwire - May 14, 2008) - CV Technologies Inc. (TSX:CVQ) today will officially open its new \$11 million headquarters and research facilities in the Edmonton Research Park allowing it to ramp up product pipeline goals as part of a five-year business plan. The new centre houses eight laboratories for its 25-person research and product development team which includes 15 PhDs.

Company President, CEO and Chief Scientific Officer, Dr. Jacqueline Shan says the new facility "will provide the science and infrastructure required to successfully support our future growth plans. The new R&D

[News Cont.](#)

facility will enable the Company to become a world class centre of excellence in the discovery and development of evidence-based natural health products (NHP) and nutraceuticals. Our goal is to become the first choice for companies wishing to engage in strategic partnerships for development and standardization of evidence-based natural ingredients utilizing the Company's patented ChemBioPrint® discovery and standardization technology. Equally importantly, this centre will support existing products and provide a pipeline engine." Last fall the Company rolled out a successful product extension to its highly popular lead product COLD-fX with an extra strength version.

Dr. Shan adds, "Discussions are continuing with potential strategic partners for the development and expansion of the Company's science to create new product opportunities worldwide through licensing, royalty, contract fees and service fees."

The Company has been recognized as a Canadian leader in scientific innovation for evidence-based naturally-derived health products. Research funding awards and financing have been provided by the National Research Council, the Alberta Heritage Foundation for Medical Research, the Alberta Ingenuity Fund and AVAC. Eighteen academic centres are part of the Company's current expert scientific collaborator network and have conducted trials or studies in areas such as immunology, infectious diseases, neurological health, blood pressure, lipid and glucose management.

The two-storey, 28,000 square foot building located in the Edmonton Research Park houses eight laboratories along with facilities for operations, public relations, finance, clinical, regulatory affairs, quality assurance and administration. The Company has 65 employees at its Edmonton location. Its sales and marketing divisions are located in leased offices in Toronto and a new office is scheduled to open in Montreal later this year. In total the company employs 85 people.